VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Halozyme Therapeutics, Inc. (HALO) Total Return Calculator with Dividends Reinvested

Halozyme Therapeutics, Inc.

Popular:

The total return for Halozyme Therapeutics, Inc. (HALO) stock is +8.66% over the past 12 months. So far it's down 6.31% this year. The 5-year total return is +37.77%, meaning $10,000 invested in HALO stock 5 years ago would be worth $13,777 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in HALO 1 year ago, it would be worth $11,174 today — you'd have gained $1,174.

With Dividends Reinvested$11,174+11.74%

Price Only (No DRIP)$11,174+11.74%

Period2025-05-06 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in HALO

1Y$10,866+$866 (+8.7%)8.7% CAGR

3Y$21,248+$11,248 (+112.5%)28.6% CAGR

5Y$13,777+$3,777 (+37.8%)6.6% CAGR

10Y$68,401+$58,401 (+584.0%)21.2% CAGR

15Y$106,070+$96,070 (+960.7%)17.1% CAGR

20Y$236,944+$226,944 (+2269.4%)17.1% CAGR

30Y$154,988+$144,988 (+1449.9%)9.6% CAGR

Halozyme Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading HALO total return...

As of 2026-05-06

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-6.31%	—	-6.31%	—	$9,369
1Y	+8.66%	8.66%	+8.66%	—	$10,866
3Y	+112.48%	28.56%	+112.48%	—	$21,248
5Y	+37.77%	6.62%	+37.77%	—	$13,777
10Y	+584.01%	21.20%	+584.01%	—	$68,401
15Y	+960.70%	17.05%	+960.70%	—	$106,070
20Y	+2269.44%	17.15%	+2269.44%	—	$236,944
30Y	+1449.88%	9.57%	+1449.88%	—	$154,988

Risk & Highlights

Best Year+328.19%2006

Worst Year-48.24%2004

Max Drawdown-31.69%2025-05-07 → 2025-05-14 · Recovered 2025-08-20

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-1.11%	-1.11%	—	+0.41%	-1.5pp
2025	+40.18%	+40.18%	—	+16.64%	+23.5pp
2024	+27.87%	+27.87%	—	+24.00%	+3.9pp
2023	-32.96%	-32.96%	—	+24.81%	-57.8pp
2022	+38.58%	+38.58%	—	-19.95%	+58.5pp

HALO underperformed the S&P 500 by 19.78pp over the past year (+8.66% vs +28.44%).

Loading summary...

HALO Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
HALOHalozyme Therapeutics, Inc.	$7.8B	+4.4%	-6.3%	+8.7%	—	+112.5%	+37.8%	+584.0%
ALNYAlnylam Pharmaceuticals, Inc.	$40.4B	-8.8%	-24.8%	+10.1%	—	+42.0%	+127.0%	+412.7%
IONSIonis Pharmaceuticals, Inc.	$12.7B	+1.2%	-5.5%	+123.6%	—	+107.9%	+88.6%	+115.6%
ARWRArrowhead Pharmaceuticals, Inc.	$11.1B	+22.6%	+10.5%	+436.0%	—	+81.1%	+12.7%	+1221.5%
EXELExelixis, Inc.	$12.4B	+1.0%	+1.9%	+11.5%	—	+128.0%	+85.3%	+847.1%
INVAInnoviva, Inc.	$1.7B	-1.6%	+14.0%	+20.9%	—	+92.8%	+96.3%	+96.4%
RCUSArcus Biosciences, Inc.	$2.6B	+17.2%	+11.9%	+191.5%	—	+33.2%	-15.8%	+53.3%
ABBVAbbVie Inc.	$362.6B	-0.2%	-8.6%	+8.6%	+3.4pp	+52.2%	+104.3%	+309.7%
AMGNAmgen Inc.	$178.7B	-3.8%	+1.4%	+21.1%	+3.4pp	+50.9%	+49.3%	+158.7%
REGNRegeneron Pharmaceuticals, Inc.	$74.9B	-8.0%	-9.4%	+17.0%	+0.6pp	-7.3%	+46.5%	+87.1%
JAZZJazz Pharmaceuticals plc	$14.3B	+13.6%	+22.6%	+79.6%	—	+52.3%	+24.3%	+45.6%

Compare:HALO vs ALNY HALO vs IONS HALO vs ARWR HALO vs ALNY vs IONS

About HALO Dividend Returns

Halozyme Therapeutics, Inc. (HALO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of HALO over the past year?

Halozyme Therapeutics, Inc. (HALO) delivered a return of 8.66% over the past year. Since HALO does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in HALO be worth today?

A $10,000 investment in Halozyme Therapeutics, Inc. one year ago would be worth $10,866 today, representing a gain of $866.

Q3Does HALO pay dividends?

Halozyme Therapeutics, Inc. (HALO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For HALO, the total return equals the price-only return.

Q4Did HALO beat the S&P 500?

No, Halozyme Therapeutics, Inc. (HALO) underperformed the S&P 500 by 19.78 percentage points over the past year. HALO delivered a total return of 8.66%, compared to the S&P 500's 28.44%. This means a passive S&P 500 index fund outperformed HALO by 19.78pp during this period.

Q5What is HALO's worst drawdown?

Halozyme Therapeutics, Inc. (HALO) experienced a maximum drawdown of -31.69% over the past year, declining from its peak on 2025-05-07 to its trough on 2025-05-14. The stock recovered to its prior peak by 2025-08-20. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is HALO's long-term total return over 10, 20, or 30 years?

Here are Halozyme Therapeutics, Inc. (HALO)'s long-term returns with dividends reinvested. Over 10 years, the total return is 584.0% (21.2% CAGR) — $10,000 would have grown to $68,401. Over 20 years: 2269.4% total return (17.1% CAGR) — $10,000 → $236,944. Over 30 years: 1449.9% total return (9.6% CAGR) — $10,000 → $154,988. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was HALO's best and worst year?

Halozyme Therapeutics, Inc.'s best calendar year was 2006 with a total return of 328.2%. Its worst year was 2004 with a total return of -48.2%. This range shows the volatility investors should expect — the difference between the best and worst year is 376.4 percentage points.